Boston, MA80 Active Studies

Pulmonary Hypertension Clinical Trials in Boston, MA

Find 80 actively recruiting pulmonary hypertension clinical trials in Boston, MA. Connect with local research sites and explore new treatment options.

80
Active Trials
58
Sponsors
12,588
Enrolling

Recruiting Pulmonary Hypertension Studies in Boston

RecruitingBoston, MANCT03888105

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab...

576 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingBoston, MANCT04557462

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A23...

540 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MANCT04580134

CLOZAPINE Response in Biotype-1

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a st...

524 participants
University of Texas Southwestern Medical Center
View Study Details
RecruitingBoston, MANCT06481891

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

The main purpose of the study is to determine the changes in symptoms and functional limitations in participants with symptomatic hypertrophic cardiomyopathy (HCM) treated with sotagliflozin as compar...

500 participants
Lexicon Pharmaceuticals
View Study Details
RecruitingBoston, MANCT04077723

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin...

498 participants
Hoffmann-La Roche
View Study Details
RecruitingBoston, MANCT06091254

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin...

478 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06935357

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine ...

454 participants
Biogen
View Study Details
RecruitingBoston, MANCT04623541

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refract...

424 participants
Genmab
View Study Details
RecruitingBoston, MANCT04924075

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Li...

322 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBoston, MANCT06090539

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrad...

308 participants
Bristol-Myers Squibb
View Study Details
RecruitingBoston, MANCT06596252

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clin...

308 participants
Dr. Falk Pharma GmbH
View Study Details
RecruitingBoston, MANCT05005975

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

To evaluate the long-term safety and tolerability of oral dersimelagon....

301 participants
Mitsubishi Tanabe Pharma America Inc.
View Study Details
RecruitingBoston, MANCT06742996

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma

The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This st...

300 participants
BeiGene
View Study Details
RecruitingBoston, MANCT05139017

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standa...

290 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBoston, MANCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

279 participants
Eli Lilly and Company
View Study Details
RecruitingBoston, MANCT06564038

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies....

276 participants
AstraZeneca
View Study Details
RecruitingBoston, MANCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid ...

275 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06561425

A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first...

274 participants
Galapagos Cell Therapeutics NV
View Study Details
RecruitingBoston, MANCT05382208

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV. The secondary objectives are to examine the effects of doxycycline on change i...

250 participants
Weill Medical College of Cornell University
View Study Details
RecruitingBoston, MANCT02227251

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated cli...

244 participants
Karyopharm Therapeutics Inc
View Study Details
RecruitingBoston, MANCT05948943

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as ...

232 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MANCT03824483

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and ven...

230 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingBoston, MANCT06643481

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of...

225 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06777901

Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone

The goal of this clinical trial is to learn if the Auryon Atherectomy System with balloon angioplasty safe and effective in treating lower limb blockages. The main question it aims to answer is: Is tr...

224 participants
Angiodynamics, Inc.
View Study Details
RecruitingBoston, MANCT05458297

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma...

223 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBoston, MANCT06568237

A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study

The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of th...

200 participants
Teva Branded Pharmaceutical Products R&D, Inc.
View Study Details
RecruitingBoston, MANCT05166161

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein cons...

200 participants
PTC Therapeutics
View Study Details
RecruitingBoston, MANCT05897424

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema...

185 participants
Sanofi
View Study Details
RecruitingBoston, MANCT06542250

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Ma...

174 participants
AstraZeneca
View Study Details
RecruitingBoston, MANCT03328078

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult p...

152 participants
Curis, Inc.
View Study Details
RecruitingBoston, MANCT05503264

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis....

152 participants
Hoffmann-La Roche
View Study Details
RecruitingBoston, MANCT06910358

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin incre...

150 participants
Disc Medicine, Inc
View Study Details
RecruitingBoston, MANCT04900623

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combi...

145 participants
Jonathan Schoenfeld, MD, MPH
View Study Details
RecruitingBoston, MANCT06581198

A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus ...

144 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MANCT06854653

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/r...

115 participants
Prescient Therapeutics, Ltd.
View Study Details
RecruitingBoston, MANCT06524375

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.

The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD ...

110 participants
Genentech, Inc.
View Study Details
RecruitingBoston, MANCT06137144

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in p...

110 participants
AstraZeneca
View Study Details
RecruitingBoston, MANCT05755386

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex media...

106 participants
Novartis Pharmaceuticals
View Study Details
RecruitingBoston, MANCT04039464

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosen...

100 participants
Johns Hopkins University
View Study Details
RecruitingBoston, MANCT05783609

Epcoritamab and Rituximab for First-line Follicular Lymphoma

The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other trea...

100 participants
Reid Merryman, MD
View Study Details
RecruitingBoston, MANCT06457503

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer....

100 participants
Coherus Oncology, Inc.
View Study Details
RecruitingBoston, MANCT03319901

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax...

82 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingBoston, MANCT02974647

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT...

82 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingBoston, MANCT05607420

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of t...

80 participants
Cellectis S.A.
View Study Details
RecruitingBoston, MANCT04895436

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previousl...

75 participants
AbbVie
View Study Details
RecruitingBoston, MANCT06848231

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multip...

75 participants
Yoda Therapeutics Inc.
View Study Details
RecruitingBoston, MANCT06347159

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multipl...

75 participants
Edgewise Therapeutics, Inc.
View Study Details
RecruitingBoston, MANCT04652882

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD....

70 participants
Vanda Pharmaceuticals
View Study Details
RecruitingBoston, MANCT05533775

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and et...

65 participants
Hoffmann-La Roche
View Study Details
RecruitingBoston, MANCT04669171

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide an...

60 participants
Enterome
View Study Details
RecruitingBoston, MANCT05465174

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma....

57 participants
Sabine Mueller, MD, PhD
View Study Details
RecruitingBoston, MANCT04647227

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment...

55 participants
American Thrombosis and Hemostasis Network
View Study Details
RecruitingBoston, MANCT04855695

Avo In R/R And Previously Untreated MCL

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (...

53 participants
Austin I Kim
View Study Details
RecruitingBoston, MANCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

52 participants
Cellectis S.A.
View Study Details
RecruitingBoston, MANCT06165341

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Maki...

50 participants
Takeda
View Study Details
RecruitingBoston, MANCT06123338

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer....

49 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingBoston, MANCT04906902

Acalabrutinib in CNSL

This research study is a Phase 1/2 clinical trial testing the safety, tolerance and efficacy of the drug Acalabrutinib for people with recurrent or refractory central nervous system lymphoma (CNSL)....

49 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingBoston, MANCT06534060

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...

46 participants
March Biosciences Inc
View Study Details
RecruitingBoston, MANCT06563596

Epco, Zanu, Ritux for R/R FL or MZL

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma ...

45 participants
Reid Merryman, MD
View Study Details
RecruitingBoston, MANCT05168930

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lympho...

45 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingBoston, MANCT03104491

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects ...

44 participants
Leland Metheny
View Study Details
RecruitingBoston, MANCT05778188

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left w...

42 participants
ReAlta Life Sciences, Inc.
View Study Details
RecruitingBoston, MANCT04656041

Folfox+Irinotecan+Chemort In Esophageal Cancer

In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal juncti...

40 participants
Massachusetts General Hospital
View Study Details
RecruitingBoston, MANCT05819866

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy....

40 participants
Minoryx Therapeutics, S.L.
View Study Details
RecruitingBoston, MANCT04560322

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in thi...

40 participants
Massachusetts General Hospital
View Study Details
RecruitingBoston, MANCT06849713

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small...

40 participants
Massachusetts General Hospital
View Study Details
RecruitingBoston, MANCT04421560

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: ...

37 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingBoston, MANCT06185764

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1....

36 participants
Vertex Pharmaceuticals Incorporated
View Study Details
RecruitingBoston, MANCT05934448

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has ...

35 participants
Jennifer Crombie, MD
View Study Details
RecruitingBoston, MANCT05313243

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymph...

32 participants
Yale University
View Study Details
RecruitingBoston, MANCT04561206

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not r...

31 participants
City of Hope Medical Center
View Study Details
RecruitingBoston, MANCT05836259

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyop...

30 participants
Tenaya Therapeutics
View Study Details
RecruitingBoston, MANCT05592015

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the...

28 participants
Jonathan Brammer
View Study Details
RecruitingBoston, MANCT06550141

Emapalumab Prevention of CAR-T Cell Associated Toxicities

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research s...

28 participants
Marcela V. Maus, M.D.,Ph.D.
View Study Details
RecruitingBoston, MANCT05583149

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. T...

27 participants
Patrick C. Johnson, MD
View Study Details
RecruitingBoston, MANCT06756308

A Study of Enasidenib in People With T-Cell Lymphoma

The researchers are doing this study to find out whether enasidenib is a safe treatment for people with angioimmunoblastic T-cell lymphoma (AITL) that has an IDH2 mutation. The researchers will look a...

25 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingBoston, MANCT04906096

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)...

25 participants
Lakshmi Nayak, MD
View Study Details
RecruitingBoston, MANCT06692452

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

This research is being done to evaluate tazemetostat in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy as a possible treatment for peripheral T-Cell Lympho...

24 participants
Eric Jacobsen, MD
View Study Details
RecruitingBoston, MANCT06679270

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy...

15 participants
Amryt Pharma
View Study Details
RecruitingBoston, MANCT06662188

JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency

This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 administered via intracerebroventricular (...

6 participants
Jaguar Gene Therapy, LLC
View Study Details

About Pulmonary Hypertension Clinical Trials in Boston

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 80 pulmonary hypertension clinical trials recruiting participants in Boston, MA. These studies are seeking a combined 12,588 participants. Research is being sponsored by Regeneron Pharmaceuticals, Novartis Pharmaceuticals, University of Texas Southwestern Medical Center and 55 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Boston — FAQ

Are there pulmonary hypertension clinical trials in Boston?

Yes, there are 80 pulmonary hypertension clinical trials currently recruiting in Boston, MA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Boston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Boston research site will contact you about next steps.

Are clinical trials in Boston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Boston studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 80 active trials in Boston are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated March 2, 2026 from ClinicalTrials.gov